FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024572430> ?p ?o ?g. }

• W2024572430 endingPage "894" @default.
• W2024572430 startingPage "885" @default.
• W2024572430 abstract "Background Hepatic metastases from neuroendocrine cancer dramatically reduce survival, introducing an important opportunity for intervention. Several treatment modalities have been examined, but an optimal treatment approach has been difficult to define. We evaluated a regimen combining hepatic artery chemoinfusion with chemoembolization. Methods Patients with neuroendocrine cancer and diffuse hepatic metastases were treated with hepatic artery chemoinfusion and chemoembolization when they demonstrated disease progression despite octreotide therapy. Four monthly cycles of 5-fluorouracil were administered via hepatic artery infusion with chemoembolization after the final 2 cycles. Response was defined by radiologic response or symptomatic improvement. Results Seventy-seven patients were treated; 18 received chemoinfusion only. The treatment-related mortality rate was 7%. The overall response rate was 80% for patients with carcinoid or islet cell neoplasms. Median progression-free survival was 19 months. Median disease-specific survival was 39 months from the first treatment; 1- and 5-year survival rates were 78% and 27%, respectively. Conclusion Survival after initiating this regimen was over 3 years for the majority of patients exhibiting progression of extensive, unresectable hepatic disease despite octreotide therapy. The addition of hepatic artery chemoinfusion to chemoembolization offers a high probability of clinical benefit to patients who, otherwise, have severely limited therapeutic options and a dismal survival. Hepatic metastases from neuroendocrine cancer dramatically reduce survival, introducing an important opportunity for intervention. Several treatment modalities have been examined, but an optimal treatment approach has been difficult to define. We evaluated a regimen combining hepatic artery chemoinfusion with chemoembolization. Patients with neuroendocrine cancer and diffuse hepatic metastases were treated with hepatic artery chemoinfusion and chemoembolization when they demonstrated disease progression despite octreotide therapy. Four monthly cycles of 5-fluorouracil were administered via hepatic artery infusion with chemoembolization after the final 2 cycles. Response was defined by radiologic response or symptomatic improvement. Seventy-seven patients were treated; 18 received chemoinfusion only. The treatment-related mortality rate was 7%. The overall response rate was 80% for patients with carcinoid or islet cell neoplasms. Median progression-free survival was 19 months. Median disease-specific survival was 39 months from the first treatment; 1- and 5-year survival rates were 78% and 27%, respectively. Survival after initiating this regimen was over 3 years for the majority of patients exhibiting progression of extensive, unresectable hepatic disease despite octreotide therapy. The addition of hepatic artery chemoinfusion to chemoembolization offers a high probability of clinical benefit to patients who, otherwise, have severely limited therapeutic options and a dismal survival." @default.
• W2024572430 created "2016-06-24" @default.
• W2024572430 creator A5013423444 @default.
• W2024572430 creator A5016193342 @default.
• W2024572430 creator A5031648774 @default.
• W2024572430 creator A5036969606 @default.
• W2024572430 date "2008-12-01" @default.
• W2024572430 modified "2023-09-25" @default.
• W2024572430 title "Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy" @default.
• W2024572430 cites W1532334298 @default.
• W2024572430 cites W1924823541 @default.
• W2024572430 cites W1986396398 @default.
• W2024572430 cites W1987586522 @default.
• W2024572430 cites W1990440729 @default.
• W2024572430 cites W1996869264 @default.
• W2024572430 cites W2000232900 @default.
• W2024572430 cites W2003860294 @default.
• W2024572430 cites W2010563015 @default.
• W2024572430 cites W2033315405 @default.
• W2024572430 cites W2038487138 @default.
• W2024572430 cites W2047757951 @default.
• W2024572430 cites W2054968877 @default.
• W2024572430 cites W207864156 @default.
• W2024572430 cites W2080222082 @default.
• W2024572430 cites W2086648036 @default.
• W2024572430 cites W2101761640 @default.
• W2024572430 cites W2107436826 @default.
• W2024572430 cites W2110922803 @default.
• W2024572430 cites W2149475754 @default.
• W2024572430 cites W2149684422 @default.
• W2024572430 cites W4241252709 @default.
• W2024572430 doi "https://doi.org/10.1016/j.surg.2008.08.037" @default.
• W2024572430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19040993" @default.
• W2024572430 hasPublicationYear "2008" @default.
• W2024572430 type Work @default.
• W2024572430 sameAs 2024572430 @default.
• W2024572430 citedByCount "50" @default.
• W2024572430 countsByYear W20245724302012 @default.
• W2024572430 countsByYear W20245724302013 @default.
• W2024572430 countsByYear W20245724302014 @default.
• W2024572430 countsByYear W20245724302015 @default.
• W2024572430 countsByYear W20245724302016 @default.
• W2024572430 countsByYear W20245724302017 @default.
• W2024572430 countsByYear W20245724302018 @default.
• W2024572430 countsByYear W20245724302019 @default.
• W2024572430 countsByYear W20245724302020 @default.
• W2024572430 countsByYear W20245724302021 @default.
• W2024572430 countsByYear W20245724302022 @default.
• W2024572430 countsByYear W20245724302023 @default.
• W2024572430 crossrefType "journal-article" @default.
• W2024572430 hasAuthorship W2024572430A5013423444 @default.
• W2024572430 hasAuthorship W2024572430A5016193342 @default.
• W2024572430 hasAuthorship W2024572430A5031648774 @default.
• W2024572430 hasAuthorship W2024572430A5036969606 @default.
• W2024572430 hasConcept C126322002 @default.
• W2024572430 hasConcept C126838900 @default.
• W2024572430 hasConcept C141071460 @default.
• W2024572430 hasConcept C143998085 @default.
• W2024572430 hasConcept C2776283816 @default.
• W2024572430 hasConcept C2776297358 @default.
• W2024572430 hasConcept C2776820930 @default.
• W2024572430 hasConcept C2779066768 @default.
• W2024572430 hasConcept C2779319517 @default.
• W2024572430 hasConcept C2781025020 @default.
• W2024572430 hasConcept C2781413609 @default.
• W2024572430 hasConcept C71924100 @default.
• W2024572430 hasConcept C90924648 @default.
• W2024572430 hasConceptScore W2024572430C126322002 @default.
• W2024572430 hasConceptScore W2024572430C126838900 @default.
• W2024572430 hasConceptScore W2024572430C141071460 @default.
• W2024572430 hasConceptScore W2024572430C143998085 @default.
• W2024572430 hasConceptScore W2024572430C2776283816 @default.
• W2024572430 hasConceptScore W2024572430C2776297358 @default.
• W2024572430 hasConceptScore W2024572430C2776820930 @default.
• W2024572430 hasConceptScore W2024572430C2779066768 @default.
• W2024572430 hasConceptScore W2024572430C2779319517 @default.
• W2024572430 hasConceptScore W2024572430C2781025020 @default.
• W2024572430 hasConceptScore W2024572430C2781413609 @default.
• W2024572430 hasConceptScore W2024572430C71924100 @default.
• W2024572430 hasConceptScore W2024572430C90924648 @default.
• W2024572430 hasIssue "6" @default.
• W2024572430 hasLocation W20245724301 @default.
• W2024572430 hasLocation W20245724302 @default.
• W2024572430 hasOpenAccess W2024572430 @default.
• W2024572430 hasPrimaryLocation W20245724301 @default.
• W2024572430 hasRelatedWork W105130885 @default.
• W2024572430 hasRelatedWork W1963972672 @default.
• W2024572430 hasRelatedWork W2003938723 @default.
• W2024572430 hasRelatedWork W2045541968 @default.
• W2024572430 hasRelatedWork W2047967234 @default.
• W2024572430 hasRelatedWork W2118496982 @default.
• W2024572430 hasRelatedWork W2413040130 @default.
• W2024572430 hasRelatedWork W2439875401 @default.
• W2024572430 hasRelatedWork W2014450888 @default.
• W2024572430 hasRelatedWork W2525756941 @default.
• W2024572430 hasVolume "144" @default.
• W2024572430 isParatext "false" @default.
• W2024572430 isRetracted "false" @default.

• next